Protalix BioTherapeutics, Inc. Earnings Per Share (Diluted)
Protalix BioTherapeutics, Inc. (PLX) reported Earnings Per Share (Diluted) of $0.05 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-12
- Protalix BioTherapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was $0.05.
- Protalix BioTherapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was $0.22.
- Protalix BioTherapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.07, a 210.54% decline year-over-year.
- Protalix BioTherapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $0.03, a 0.00% change year-over-year.
- Protalix BioTherapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$0.08, a 300.00% decline from fiscal 2024.
- Protalix BioTherapeutics, Inc. earnings per share, diluted for fiscal 2024 was $0.04, a 55.56% decline from fiscal 2023.
- Protalix BioTherapeutics, Inc. earnings per share, diluted for fiscal 2023 was $0.09.
- Protalix BioTherapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$0.31.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.05 10-Q · filed 2026-08-12 | $0.27 10-Q · filed 2026-08-12 | $0.20 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.23 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||
| 2026-03-31 | $0.22 10-Q · filed 2026-05-13 | $0.16 derived: net income ÷ weighted average shares · filed 2026-05-13 | $0.19 derived: net income ÷ weighted average shares · filed 2026-05-13 | $0.19 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||
| 2025-12-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.08 10-K · filed 2026-03-18 | ||
| 2025-09-30 | $0.03 10-Q · filed 2025-11-13 | $0.03 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.01 10-Q · filed 2025-11-13 | $0.06 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | -$0.04 10-Q · filed 2026-08-12 | $0.04 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.07 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||
| 2025-03-31 | -$0.05 10-Q · filed 2026-05-13 | $0.03 derived: net income ÷ weighted average shares · filed 2026-05-13 | $0.06 derived: net income ÷ weighted average shares · filed 2026-05-13 | |||
| 2024-12-31 | $0.06 derived: net income ÷ weighted average shares · filed 2026-03-18 | $0.10 derived: net income ÷ weighted average shares · filed 2026-03-18 | $0.04 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $0.03 10-Q · filed 2025-11-13 | -$0.05 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | -$0.03 10-Q · filed 2025-08-14 | -$0.09 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$0.06 10-Q · filed 2025-05-09 | |||||
| 2023-12-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-03-18 | $0.10 derived: net income ÷ weighted average shares · filed 2026-03-18 | $0.09 10-K · filed 2026-03-18 | ||
| 2023-09-30 | -$0.04 10-Q · filed 2024-11-14 | $0.17 derived: net income ÷ weighted average shares · filed 2024-11-14 | $0.16 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $0.21 10-Q · filed 2024-08-14 | $0.18 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | -$0.05 10-Q · filed 2024-05-10 | |||||
| 2022-12-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$0.15 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$0.26 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$0.31 10-K · filed 2025-03-17 | ||
| 2022-09-30 | -$0.07 10-Q · filed 2023-11-06 | -$0.18 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$0.24 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$0.11 10-Q · filed 2023-08-07 | -$0.16 10-Q · filed 2023-08-07 | ||||
| 2022-03-31 | -$0.05 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | -$0.62 10-K · filed 2024-03-14 | |||||
| 2021-09-30 | -$0.09 10-Q · filed 2022-11-14 | -$0.48 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | -$0.25 10-Q · filed 2022-08-15 | -$0.39 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | -$0.14 10-Q · filed 2022-05-16 | |||||
| 2020-12-31 | -$0.22 10-K · filed 2023-02-27 | |||||
| 2020-09-30 | -$0.14 10-Q · filed 2021-11-15 | -$0.25 10-Q · filed 2021-11-15 | ||||
| 2019-12-31 | -$1.23 10-K · filed 2022-03-31 | |||||
| 2018-06-30 | -$0.06 10-Q · filed 2019-03-18 | -$0.08 10-Q · filed 2018-08-09 | -$0.11 10-Q · filed 2019-03-18 | -$0.14 10-Q · filed 2018-08-09 | ||
| 2017-06-30 | -$0.06 10-Q · filed 2019-03-18 | -$0.47 10-Q · filed 2019-03-18 | ||||
| 2016-06-30 | -$0.11 10-Q · filed 2017-08-09 | -$0.20 10-Q · filed 2017-08-09 | ||||
| 2013-06-30 | -$0.07 10-Q · filed 2013-08-08 | -$0.12 10-Q · filed 2013-08-08 | ||||
| 2012-06-30 | $0.10 10-Q · filed 2013-08-08 | $0.04 10-Q · filed 2013-08-08 | ||||
| 2011-06-30 | -$0.16 10-Q · filed 2012-08-03 | -$0.22 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |